Broad-spectrum antiviral capsules

Triazavirin (Riamilovir)

triazaverin.png

Pharmachal has secured regional distribution for the novel, broad-spectrum antiviral capsule Triazavirin (Riamilovir), which has indications registered for antiviral activity against viruses including Influenza SARS A & B, Upper Respiratory Track Viral Infections, and has shown clinically to be effective against SARS-CoV-2, the virus that causes COVID-19.

The Company has imported stocks into Australia for prescription to patients under the TGA's Special Access Scheme. Pharmachal has appointed a regulatory consultant to prepare the documentation for registration of the drug as an antiviral SARS A & B flu drug. 

2020 Clinical Testing in Russia and China, and observational reports from Kenya, found that Triazavirin delivered significant antiviral activity against SARS-CoV-2.  Over three million patients have taken TZV to treat Covid-19 since the beginning of the pandemic and many more for influenza.

Pharmachal also plans to reformulate Triazavirin into a nasal spray utilizing the company’s proprietary nano drug delivery technology.